



ADULT MEDICATION GUIDELINE

Sotrovimab (Covid-19)

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Restrictions

Non-Formulary –

This medicine is part of the National Medical Stockpile (NMS) for the treatment of COVID-19. Refer to [Statewide Medicines Formulary – sotrovimab injection](#) for more information

HIGH RISK Medication 

Synonym

Xevudy®

Presentation

Vial: 500mg/8mL

Preparation, Dose and Administration

Sotrovimab Preparation Video: [WNHS Sotrovimab Preparation](#)

[FSFHG Sotrovimab Intravenous Drug Administration Guideline](#)

[KEMH Sotrovimab \(COVID-19\) Infusion Chart](#)

Related Policies, Procedures & Guidelines

[Statewide Medicines Formulary – sotrovimab injection](#)









[Patient Information Leaflet](#)

[WA Health Patient Consent Form - Sotrovimab](#)

[WA Emergency COVID-19 Treatment Approval – Sotrovimab](#)

[Model of Care for Sotrovimab](#)

[Guidelines for use of Sotrovimab for COVID-19](#)

Keywords	Sotrovimab				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	Feb 2022 – Inaugural version March 2022 – Added preparation video and KEMH Sotrovimab Chart				
Date First Issued:	Feb 2022	Last Reviewed:	Feb 2022	Review Date:	Feb 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	Mar 2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.